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Abstract
Background: Micronutrient deficiencies including selenium (Se) are widespread in Malawi and potentially underlie
a substantial disease burden, particularly among poorer and marginalised populations. Concentrations of Se in
staple cereal crops can be increased through application of Se fertilisers – a process known as agronomic
biofortification (agro-biofortification) – and this may contribute to alleviating deficiencies. The Addressing Hidden
Hunger with Agronomy (AHHA) trial aims to establish the efficacy of this approach for improving Se status in rural
Malawi.
Methods: A double-blind, randomised, controlled trial will be conducted in a rural community in Kasungu District,
Central Region, Malawi. The hypothesis is that consumption of maize flour agro-biofortified with Se will increase
serum Se concentration. We will recruit 180 women of reproductive age (WRA) (20–45 years) and 180 school-age
children (SAC) (5–10 years) randomly assigned in a 1:1 ratio to receive either maize flour enriched through agro-
biofortification with Se or a control flour not enriched with Se. Households will receive flour (330 g per capita per
day) for 12 weeks. The primary outcome is Se concentration in serum (μg/L). Serum will be extracted from venous
blood samples drawn at baseline (prior to flour distribution) and end-line. Selenium concentration will be measured
by using inductively coupled plasma mass spectrometry.
Discussion: Findings will be communicated to policy stakeholders and participating communities and reported in
peer-reviewed journals.
Trial registration: The Addressing Hidden Hunger with Agronomy (Malawi) trial is registered (5th March 2019;
ISCRTN85899451).
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Background
Micronutrient deficiencies are widespread in Malawi [1].
Selenium (Se) is an essential micronutrient with import-
ant roles in thyroid function and cognitive development
and as a component of selenoprotein anti-oxidants [2,
3]. In a recent study of a nationally representative sam-
ple of Malawian women and pre-school children, plasma
Se concentrations were below the threshold for optimal
activity of the anti-oxidant enzyme glutathione peroxid-
ase 3 (GPx3) in 62% of women (15–49 years; n = 754)
and 86% of pre-school children (6–59 months; n = 990)
[4]. Deficiency of Se occurs because of inadequate diet-
ary Se intakes and this is driven by low concentrations
of plant-available Se in the weathered agricultural soils
that are typical of Malawi [5–7].
There are various potential strategies – including diet-
ary diversification, food fortification at processing stage,
and supplementation – to alleviate Se deficiencies. Alter-
natively, the concentration of bioavailable Se can be in-
creased in the edible portion of staple crops – a process
known as biofortification. For some micronutrients, bio-
fortification can be achieved through crop breeding [8],
but agro-biofortification (i.e., application of micronu-
trient fertilisers) is required for Se because of the domin-
ance of environmental over genetic controls of Se
concentration in crops [9]. Agro-biofortification of maize
can increase concentrations of Se in grain and may be a
cost-effective and equitable strategy in Malawi, where
maize contributes 60% of dietary energy supply and
more among poorer populations [5, 7].
Agro-biofortification with Se has policy precedent in
Finland, where incorporation of Se into granular fertili-
sers has been mandatory since 1984. Mean plasma Se
concentrations of adults (n = 60) increased from 70.3 μg/
L prior to the fertiliser policy change in 2010 to
110.5 μg/L, which is considered optimal status [10].
However, this strategy has not been implemented in
low- to middle-income countries where agriculture, food
systems and dietary patterns are substantially different
from those in high-income countries.
This study aims to test the efficacy of improving Se
status among a rural Malawian population through
consumption of maize flour enriched with Se through
agro-biofortification. The evidence may inform fertiliser
policies in Malawi.
Methods and design
The study protocol is reported according to SPIRIT
guidelines [11] (Additional file 1).
Study setting
The Addressing Hidden Hunger with Agronomy
(AHHA) Malawi trial will be conducted in Wimbe Trad-
itional Authority (TA), Kasungu District, Central Region,
Malawi. The study area was selected because of the high
prevalence of Se deficiency [4]. Most households rely on
subsistence farming alongside smallholder and estate to-
bacco production [12]. To define a study area, two
neighbouring enumeration areas (EAs) were randomly
selected from a total of 51 EAs in Wimbe TA; EAs
are the primary sampling unit of the national Demo-
graphic and Health Survey (DHS). We conducted a
census to create a list of all households in the EA
(n = 1179) and a roster of all household members.
Study design
The AHHA Malawi trial is a two-arm randomised, double-
blind, controlled trial with participants receiving maize
Fig. 1 CONSORT diagram of the Addressing Hidden Hunger with Agronomy (AHHA) Malawi trial. The trial aims to recruit 180 school-age children
(SAC) and 180 women of reproductive age (WRA)
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flour enriched through agro-biofortification with Se or a
control flour that is not enriched with Se (Fig. 1).
Prior to baseline assessments, 180 households will be
randomly selected from eligible households (see ‘Inclu-
sion criteria’). An additional 50 households will be pre-
selected in case of consent refusals. Households will be
visited for recruitment of one non-pregnant woman of
reproductive age (WRA) (20–45 years) and one school-
age child (SAC) (5–10 years). Recruitment and baseline
questionnaires will be conducted in the household and
participants will then be directed to nearby mobile field
clinics set up in large tents where anthropometry and
blood sampling will be conducted. Recruitment will be
conducted by trained research assistants (RAs) hired by
Lilongwe University of Agriculture and Natural Re-
sources (LUANAR). The trial aims to recruit 180 WRA
and 180 SAC.
After baseline, households will be randomly allo-
cated in a 1:1 ratio to receive Se flour (n = 90) or
control flour (n = 90). The trial statistician will allo-
cate households remotely by using a computer-based
randomisation programme. Intervention allocation will
be concealed from participants, RAs conducting the
baseline and end-line surveys, laboratory analysts and
those involved in managing or overseeing the trial.
Locally, only the supervisor of the maize flour distri-
bution will know the allocation of households to
treatments.
Inclusion criteria
Household level:
 Household members include at least one non-
pregnant WRA (age 20–45 years) and at least one
SAC (age 5–10 years) in residence during July to
October.
 Household typically prepares and consumes meals at
home.
 Household head agrees that the household will
receive and all members consume maize flour in
place of their own flour for the 12-week flour
distribution period.
Individual level:
 One non-pregnant WRA (age 20–45 years) and one
SAC (age 5–10 years) per household. Pregnancy
status is self-reported.
 Participant is planning to be in residence in the
household during July to October.
 Participant WRA is willing and able to provide
consent, and the caretaker of the participant SAC is
willing and able to provide assent.
Formative work
The trial delivery team have undertaken substantial pre-
paratory work with the community. Formative work was
conducted from July to September 2018 to identify
potential concerns among community members about
participation in the trial and to develop mitigating
strategies. Community engagement activities have been
conducted and these include briefings with traditional
leaders and relevant government officials, question-and-
answer sessions with each village in the study area, and a
community visit to the maize production site.
Description of treatment
The flour distribution period will last 12 weeks during
July to October 2019. The intervention will begin 1–2
weeks after the baseline assessment is complete. End-
line blood samples will be taken 1–2 weeks prior to the
final flour distribution (Fig. 2).
Maize flour will be distributed to intervention and
control households in multiples of 5- and 10 kg sacks at
pre-determined distribution points set up in the vicinity
of the villages. Households will receive sufficient maize
flour to meet requirements for the 12-week flour distri-
bution period with distributions at six time points.
Household requirements will be calculated on the basis
of estimated consumption of 330 g/capita/day for all
household members over the age of 1 year (equivalent to
10 kg /capita/month).
The provision of non-biofortified flour to control
households allows the trial to be blinded. However, bags
of maize flour will be labelled to ensure that households
receive the correct treatment and to monitor consump-
tion. The trial statistician will generate a set of unique
seven-digit codes that will be used to label the bags of
study flour. The statistician will communicate the treat-
ment codes directly to the maize flour distribution team
lead. Only the trial statistician and maize distribution
team will know how to interpret the code. The rest of
the trial team and participants will be blinded to treat-
ment allocation. At distribution points, study flour bags
will be stacked in piles according to the bag code. Partic-
ipants will present their ID cards (Additional file 2i) and
the maize distribution team will check their allocated
treatment before providing the correct quantity and type
of flour. Participants will receive help transporting maize
flour to their home if necessary.
Non-participating households in the study area will
also receive non-biofortified flour for the duration of the
study. Control-equivalent flour will not be labelled with
codes and will be distributed separately. The provision
of free flour to non-participant households was deemed
appropriate to prevent individuals from feeling coerced
into participating in the trial, to avoid envy or stigma
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within the community, and to reduce the likelihood of
sharing flour between households.
The trial maize was grown at LUANAR, Bunda Cam-
pus, Malawi. A widely grown hybrid cultivar (DKC80–
53) was grown by using conventional agronomy. Plants
were spaced at 0.25 m within rows; the distance between
rows was 0.75 m. When the crop was approximately 1–
1.5 m in height, at the pre-tasselling stage, sodium selen-
ate solution was sprayed continuously along the tops of
ridges (stem bases) at 18 g Se/ha (elemental basis)
applied by using knapsack sprayers and an application
volume of 100 L water/ha [13]. Maize grain was sampled
when the crop was mature, about 1 month prior to har-
vest, and analysed by inductively coupled plasma mass
spectrometry (ICPMS). At harvest, the mean concentra-
tions of Se were 0.010 mg/kg in control grain and 0.279
mg/kg in Se-biofortified grain. The Se-biofortified grain
will be blended in a 2:1 ratio with control grain to obtain
a concentration of 0.2 mg/kg, the target for the interven-
tion flour. In comparison, the median Se concentration
in maize grain samples from farmer fields on non-
calcareous soil types in Malawi was 0.015 mg/kg (n =
105) [5, 7, 14]. Grain will be milled and packed in
labelled sacks. Milling equipment will be thoroughly
cleaned between processing the Se-biofortified and
control grain.
Maize flour in Malawi comes in three main types:
ufa mgaiwa (unrefined), ufa granmill (partly refined
with bran removed) or ufa woyera (fully refined with
bran and endosperm removed). We will provide ufa
granmill during the trial as this was the preferred
type of flour among participants in formative
research.
Objectives
The objective of the study is to test whether the Se sta-
tus of non-pregnant WRA and SAC can be improved
through consumption of maize flour enriched with Se
through agro-biofortification. We hypothesise that diet-
ary Se intake will be substantially greater among those
receiving Se-biofortified maize flour compared with con-
trol flour and that this will translate into increased Se
status among those receiving fortified maize measured
as serum Se concentration.
Initially, the trial was designed to test the efficacy of
alleviating Se and zinc (Zn) deficiency (May 2019;
ISRCTN85899451). However, in production of the maize
for the study, the target maize Zn concentration was not
reached and this was likely due to a combination of soil
factors and heavy rainfall during the 2018/19 production
season. Therefore, the planned Zn arm of the trial was
underpowered and dropped for ethical reasons.
Outcome measures
Primary outcome measure
Serum Se concentration Serum Se concentrations will
be measured at baseline and end-line. Whole venous
blood will be drawn into trace element–free tubes (BD
Diagnostics, Eysins, Switzerland); after clotting, the serum
will be separated by centrifugation within 40min. Serum
0.5-mL aliquots will be transferred into cryovials, trans-
ported in mobile freezers and stored at −80 °C. Serum
samples will be shipped on dry ice to the University of
Nottingham, UK, for determination of elemental Se
concentration by ICPMS [4]. The unit of measure is con-
centration of Se in serum (μg/L).
Fig. 2 Schedule of enrolment, interventions, and assessments for the Addressing Hidden Hunger with Agronomy Malawi trial
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Secondary outcomes
The prevalence of Se deficiency will be compared be-
tween treatment groups. Deficiency will be defined by
using established thresholds for the optimal activity of
GPx3 (<84.9 μg/L) and iodothyronine deiodinase (IDI)
(<64.8 μg/L) and for Keshan disease (<30 μg/L), which
is a cardiomyopathy linked to Se status reported in
China [15].
Concentration in serum of the markers of inflammation
alpha (1)-acid glycoprotein (AGP) (mg/L) and C-reactive
protein (CRP) (mg/L) will be measured by using a sand-
wich enzyme-linked immunosorbent assay (ELISA).
Concentration of haemoglobin in whole venous blood
(g/dL) will be measured in the field by trained nurses
using a portable HemoCue Hb201+ (HemoCue AB,
Ängelholm, Sweden).
The prevalence of anaemia will be compared between
treatment groups. Anaemia will be defined by using
standard thresholds [16].
Dietary Se intakes will be quantified among WRA.
Dietary data will be collected among participating WRA
using four-pass interactive 24-h recall. Two days before
the 24-h recall, participants will be given plates/bowls
and asked to consume foods on a plate separate from
other family members. In the first pass, participants will
be asked to recall all foods and beverages they consumed
over the previous day (from midnight to midnight). In
the second pass, they will be asked details about the
foods/beverages and time/place of consumption. In the
third pass, they will be asked to estimate the quantity of
each food/beverage consumed by using an interviewer-
assisted method (e.g., food models and diet scales) and
the source of each food (i.e., home produced, purchased,
the AHHA project, from neighbours/relatives, gifted,
food aid/food for work or wild). In the fourth pass, the
recalled intake over the day will be reviewed. Dietary
data will be collected across all days of the week (popu-
lation level) to account for any day-of-the-week effect. A
repeat 24-h recall will be collected from a sub-sample of
participants (n = 60) at least 2 days after the initial recall.
Dietary data will be combined with relevant food com-
position data [7] to determine the baseline intakes of
energy and micronutrients. The percentage of women at
risk of inadequate intakes of Se will be estimated by
using the Estimated Average Requirement (EAR) cut-
point method [17] after adjustment for intra-subject
variability. The percentage of energy from food groups,
sub-groups and specific foods will be estimated to exam-
ine changes in diet patterns.
Morbidity outcomes will be self-reported at baseline and
end-line by using standard questions from the Malawi
DHS. Diarrhoea incidence, severity and duration, incidence
of vomiting and incidence of fever will be recorded for
WRA and SAC. Prevalence of pneumonia will be self-
reported among SAC only (as per the DHS) (i.e., number of
days of coughing and fast or difficult breathing (due to a
problem in the chest) in the two weeks prior to the survey).
Monitoring of adherence
Participant consumption of flour will be monitored during
the course of the intervention. Households will be visited
once every 15 days. RAs will observe the number of 10 kg
bags of study flour that have not been consumed and will
count and collect the number of empty bags of study flour
for reconciliation. A household member responsible for
meal preparation will be asked what flour was used the
previous day for each meal and what quantity of non-
study flour was used by the household over the past two
weeks. The same member of the household will be asked
how many bags of study flour have been sold or gifted
away. Combined, these data will provide a proxy measure
of household consumption. Data collected for the moni-
toring of adherence will not be used to alter the amount
of study flour received by participating households at
future distribution time points.
Monitoring of participant safety
Consumption of 330 g/capita/day of the agro-biofortified
maize flour with Se concentration of about 0.3 mg/kg
would supply 99 μg Se/capita/day. The adult recom-
mended dietary allowance for Se is 55 μg/capita/day and
the tolerable upper level of intake is 400 μg/day [18].
The concentration of Se in maize grain depends largely
on soil factors, and the concentration in Se-biofortified
grain (mean 0.279 mg/kg) produced for this study is
within the “natural” range of maize grain Se concentra-
tions observed previously in Malawi (0.005–0.533 mg/
kg) [5]. Comparatively greater Se concentrations occur
naturally (i.e., without addition of Se fertiliser) in maize
grown on Eutric Vertisol soil types, found in southern
Malawi in the Shire Valley and along the shore of Lake
Malawi.
Consumption of Se-biofortified flour in the quantities
provided in this study is not known or expected to cause
adverse events (AEs). Procedures will be set up to capture
and monitor safety. Non-serious AEs will be captured and
recorded in electronic monitoring forms by RAs during
adherence monitoring visits to participating households
(every 15 days). RAs will ask participants and caregivers of
children about any AEs, including fever, diarrhoea and
coughing. These will be compiled and reported to the
principal investigator (PI) on a monthly basis.
Serious adverse events (SAEs) include death, life-
threatening illness, hospitalisation, persistent or significant
disability, or other such occurrences, and these will be re-
ported to the study coordination centre (LUANAR)
through completion of an SAE form and submission within
24 h of the monitoring team being made aware of the event.
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Participants will be informed how to contact the study co-
ordination centre; and RAs, health surveillance assistants
and health volunteers will be trained on how to record and
report SAEs. A medical doctor will be “on call” and avail-
able to visit participants through the duration of the inter-
vention to advise on seriousness and causality. The study PI
(Edward Joy) will record the event and its seriousness, caus-
ality and expectedness.
The PI will report SAEs to the trial statistician who is
aware of random treatment allocation and who will re-
port to the independent statistician on the trial steering
committee (TSC) to decide about the continuation of
the trial. All AEs and SAEs will be compiled by the PI
and reported to the research ethics committees (RECs)
in accordance with their criteria.
Unblinding will occur only at the request of the inde-
pendent statistician on the TSC. Unblinding would in-
volve revealing the allocation of households to treatment
(e.g., to investigate the occurrence of SAEs and their
association with treatment). At this point, the TSC may
request that the trial be paused or terminated.
Withdrawal
Any individual will remain free to withdraw at any time
from the study. If a participant withdraws consent from
further trial participation, their data will remain on file
and will be included in the final study analysis. If a par-
ticipant withdraws consent for their data to be used, the
data will be destroyed immediately.
Loss to follow-up
Households or individuals that move out of the village
will leave the trial and no attempt will be made to follow
them up. Any data collected from participants who are
lost to follow-up will be included in the analysis where
possible. Continued community engagement will be con-
ducted to minimise loss to follow-up. Contact details, in-
cluding mobile phone numbers, have been recorded
during household enumeration, and participants will be
contacted 1–2 days before the mobile clinic is set up in
their vicinity. Mobile clinics will be located close to par-
ticipant households, and transport will be provided if
participants require. Also, participants will be contacted
1–2 days prior to flour distribution.
Data collection and management
All participants will be assigned a unique numeric ID
that will be used in data capture forms and subsequent
analyses to maintain anonymity. Questionnaire, anthro-
pometry and adherence data will be collected by trained
RAs in the field via passcode-protected tablets using an
Open Data Kit (ODK) [19]. Blood samples will be taken
by trained and experienced nurses and processed to
serum by trained technicians. Sample tubes and
subsequent data will be labelled with unique, anonymous
codes. Samples will be logged in the field using ODK
forms. Completed forms will be uploaded to a secure
cloud server daily and will be encrypted for security.
Mobile clinic team leads will report daily to the anthro-
pometry and blood collection team supervisors to ensure
that standard procedures are followed. The trial manager
and data manager will reconcile samples and data forms
daily. Recruitment rates and number of eligible individ-
uals will be assessed and compared with numbers en-
rolled and completeness of follow-up.
Dietary data will be collected by trained RAs by using
a paper-based data collection process. Dietary forms will
be labelled with participant IDs. Data collection will be
supervised by the diet team supervisor, who will observe
individual 24-h recalls and check the data collected each
day. The RA, supervisor and coordinator will sign off all
forms before they are filed for data entry. Quality control
checklists (for observations and forms) will be used to
ensure that standard procedures are followed. At the
end of the baseline and end-line surveys, all diet data
will be double-entered to reduce errors and ensure that
consistent data entry decisions are made.
The data manager will hold the data tables that match
participant ID to sample codes, and these will not be
available to the trial statistician until after statistical ana-
lyses are complete. Thus, the trial statistician will be
blinded to treatments. Sample analysis will be under-
taken by Malawian and UK study collaborators in la-
boratories in the UK. Good practices in quality control
will be followed, such as analysis in duplicate and inclu-
sion of sample blanks and reference materials and use of
sufficiently sensitive analytical instrumentation to ensure
quantification of the variables of interest.
All data collection and storage will be compliant with
the General Data Protection Regulation [20] and the
conditions of the REC approval. Anonymised data will
be uploaded to an open data platform following analysis
in compliance with open access data requirements. Data
will be kept for a minimum of 10 years after completion
of the trial.
Biological sample management
Serum samples will be transported in cool boxes packed
with ice from mobile field clinics to the Community Health
Sciences Unit, Ministry of Health, Area 3, Lilongwe, where
they will be stored at −80 °C. Cryovials and cryovial racks
will be labelled with unique numeric and quick response
(QR) codes. Instrumentation and methodologies are not
established in Malawi for ICPMS to measure elemental
concentrations in the parts-per-billion range. Samples will
be transferred on dry ice to a secure laboratory at the Uni-
versity of Nottingham under a material transfer agreement
(MTA) with appropriate licences. Samples will be cross-
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checked with shipment lists. Following ICPMS analysis,
samples will be stored for a period of 5 years following
completion of the trial after which they will be destroyed in
accordance with licence and safety requirements.
Statistical analysis
The trial is designed to have statistical power to detect
an increase in Se concentration in serum of 4.9 μg/L
with 5% significance and 90% power, allowing for 20%
dropout, based on a standard deviation of 9.0 μg Se/L
(standardised difference of 0.54). In a recent national
survey, the mean plasma Se concentration among adult
women in Malawi was 83.7 μg/L [4], and the trial is
powered to increase Se concentration above the thresh-
old for optimal activity of GPx3 (<84.9 μg/L).
Data on the number of participants (WRA and
SAC) randomly assigned (with exclusions and reasons
for exclusion), the flow of participants through enrol-
ment, allocation to intervention, follow-up and ana-
lysis will be presented in a flow chart. The primary
analysis will be carried out on groups as randomised
(‘intention to treat’).
Tabulation of demographic data and other characteris-
tics will be carried out by using the intention-to-treat
datasets. No significance tests will be performed to test
for differences at baseline. Descriptive statistics for con-
tinuous variables will include the mean, standard devi-
ation, median, range and the number of observations.
Categorical variables will be presented as numbers and
percentages.
For the primary outcome, analysis of covariance
(adjusting for baseline values) will be used to estimate
a mean difference in Se status between the two arms
of the trial. The results will be presented with a 95%
confidence interval. For secondary outcomes, appro-
priate models will be used to examine the effect of
the relevant intervention. Appropriate measures of ef-
fects will be reported with 95% confidence intervals.
Unadjusted and adjusted results will be presented
for all analyses. Planned subgroup analyses for WRA
will include 10-year age groups (20–29, 30–39 and
40–45 years), lactation status ('yes – exclusive breast-
feeding'; 'yes – breastfeeding and complementary
feeding'; 'not breastfeeding'), and pregnancy status
(self-reported at end-line). All sub-group analyses will
be performed by including a variable (or variables, as
appropriate) for the sub-group and its interaction
with the treatment in the model. Results will be inter-
preted with due caution. Full details of all analyses,
including any additional covariates to be included in
the adjusted models, will be set out a priori in a stat-
istical analysis plan.
Although we have allowed for 20% missing data in
the sample size calculations, only a small amount of
missing data is expected and it is unlikely that it will
have to be accounted for in any analysis. We would
consider using multiple imputation if missing data
were larger than expected or there were differential
attrition between the trial arms. We would also at-
tempt to ensure that the reason for the differential at-
trition was fully understood.
Discussion
The AHHA Malawi trial is a pragmatic, community-
based trial that will provide evidence on the efficacy of
alleviating Se deficiency through consumption of maize
flour enriched with Se through agro-biofortification.
Agro-biofortification may be a cost-effective way to alle-
viate Se deficiency in Malawi; previous studies estimate a
cost-per-alleviated case of about USD $0.36 per year [7].
The evidence from the trial may be used to inform fu-
ture agriculture policy in Malawi and the wider region.
The trial findings will be communicated to policy stake-
holders and participating communities and reported in
peer-reviewed journals.
Trial status
Protocol version 4.2. Recruitment started on 26 June
2019 and was completed on 6 July 2019.
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